Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the publication of positive phase II results with its ToleroMune(R) cat allergy treatment in the Journal of Allergy and Clinical Immunology (JACI). The results show that cat allergy patients who received four doses of ToleroMune(R) treatment over 12 weeks maintained a significantly greater improvement in symptoms one year after the start of the study compared with placebo (p=0.0104)...
More...
More...